Humanin for Health & Longevity - Quick Reference Sheet

Humanin for Health & Longevity

Created on 07/01/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

Humanin is a small mitochondrial protein that helps keep cells alive under stress. Blood levels fall with age, and children of very long-lived people carry high levels. Laboratory and animal work suggests protection for nerve cells and metabolism, but one animal study found it may speed cancer growth, and no human trials confirm benefit or safety. (Full Review)

Protocol

Form
HNG analogue
Stable S14G-humanin used in place of native humanin
Route
Subcutaneous injection
Subcutaneous dosing described in practitioner guides
Frequency
Twice weekly
Intermittent single doses rather than daily split dosing
Time to effect
Metabolic & inflammatory changes
Weeks (animal)
Unknown in humans; no human onset data exist

Benefits

Contraindications
  • Active cancer or recent cancer history
  • Pregnancy or breastfeeding
Key Interactions
  • Glucose-lowering drugs (insulin, sulfonylureas such as glipizide)
  • Blood-glucose OTC agents (high-dose niacin)
  • Other experimental mitochondrial peptides (MOTS-c, SHLP2)
  • Glucose-lowering or mitochondrial supplements (berberine, alpha-lipoic acid)
  • Cancer therapies (chemotherapy, radiation)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Tumor-promoting potential; unknown long-term safety of exogenous administration
  • Speculative: Injection-site and immunogenic reactions; disruption of normal apoptotic balance

Monitoring

Marker Target Why
Fasting glucose 75–90 mg/dL Detects added glucose-lowering effect
Fasting insulin 2–6 µIU/mL Tracks insulin-sensitivity changes
HbA1c <5.4% Longer-term glucose control
hs-CRP <1.0 mg/L Systemic inflammation marker
CBC Within normal limits General safety/immune screen
Comprehensive metabolic panel Within normal limits Kidney/liver safety screen
Cancer screening (age-appropriate) No active disease Screens the key contraindication

Cadence: Baseline, then at 4 weeks, 12 weeks, and every 3–6 months thereafter, with earlier review if any adverse change occurs.

Qualitative Assessment

  • Energy levels and exercise tolerance
  • Cognitive clarity and memory
  • Sleep quality
  • General sense of recovery and well-being